Pattern recognition analysis of <sup>1</sup>H NMR spectra from perchloric acid extracts of human brain tumor biopsies

Maxwell, Ross J.; Martínez-Pérez, Irene; Cerdán, Sebastián; Cabañas, Miquel E.; Arús, Carles; Moreno, Àngel; Capdevila, Antoni; Ferrer, Enrique; Bartomeus, Frederic; Aparicio, A.; Conesa, Gerard; Roda, J.M.; Carceller, Fernando; Pascual, José M.; Howells, Sían; Mazucco, Roy A; Griffiths, John R.

doi:10.1002/mrm.1910390604

Cited by 68 publications

(45 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Every other week, NMR scans were performed to follow the fate of tumors, using a General Electric Orizon 1-Tesla machine under conditions dedicated to skull analysis. 23 Mice were sacrificed at indicated time points and further examined by means of histological sections.…”

Section: Animal Studiesmentioning

confidence: 99%

Tumor suppressive activity of a variant isoform of manganese superoxide dismutase released by a human liposarcoma cell line

Mancini

Borrelli

Schiattarella

et al. 2006

Intl Journal of Cancer

View full text Add to dashboard Cite

A cell line derived from a pleiomorphic liposarcoma, named LSA, was previously reported to secrete (a) factor(s) exhibiting oncotoxic properties. The present article describes the isolation, purification and sequence analysis of a protein released by LSA cells into conditioned culture medium. This protein proved to be a variant isoform of manganese superoxide dismutase (MnSOD), hence its designation as LSA-type-MnSOD. This LSA-type-SOD differed from conventional SODs in its secretion by producer cells, contrasting with the normal localization of SODs in the mitochondrial matrix. Interestingly, during the protein purification process, LSA-type-SOD cosegregated with a cytotoxic activity directed against a number of tumor cell lines, as determined under in vitro conditions. This cytopathic effect was most likely due to LSAtype-SOD, since it could be fully reproduced using recombinant SOD that was expressed from cDNA clones isolated from LSA cells mRNA preparations and henceforth designated L-rSOD. In addition to its manifestation in cell lines kept in tissue culture, the oncotoxicity of LSA-type-SOD was further reflected in a remarkable capacity of this protein for suppression of mammary tumors in Balb-C-FR III mice. Animals subcutaneously injected with L-rSOD in the tumor area showed a complete disruption of established mammary carcinomas, as monitored by nuclear magnetic resonance (NMR) scanning. Moreover, metastatic spreading, which was readily detected in the control group, was suppressed in the treated animals. Altogether these data suggest that LSA-type-SOD interferes with survival and spreading of neoplastically transformed cells and deserves to be future validated as a therapeutic agent against cancer, either alone or in combination with conventional treatments. ' 2006 Wiley-Liss, Inc.

show abstract

Section: Animal Studiesmentioning

confidence: 99%

Tumor suppressive activity of a variant isoform of manganese superoxide dismutase released by a human liposarcoma cell line

Mancini

Borrelli

Schiattarella

et al. 2006

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…In addition, HR-MAS NMR spectroscopy of intact tissues (ex vivo) provides further advantages over traditional high resolution liquid NMR of tissue extracts (in vitro) (27,34). High resolution NMR of extracts from excised tissues requires large amounts of sample (35). Likewise, the extraction process via protein precipitation methods disables the direct observation of small cellular proteins and membrane semi-mobile lipids.…”

Section: Introductionmentioning

confidence: 99%

Metabolic profile of chronic liver disease by NMR spectroscopy of human biopsies

Monleνn

2010

Int J Mol Med

View full text Add to dashboard Cite

Abstract. Among the different processes occurring during the evolution of liver disease, fibrosis has a predominant role. Liver fibrosis mechanisms are fairly constant irrespective of the underlying etiology. Cirrhosis is the end-stage of this reaction. Metabolic profiles, which are affected by many physiological and pathological processes, may provide further insight into the metabolic consequences of this severe liver disease. The aim of this study was to demonstrate the applicability of 1 H high resolution magic angle spinning (HR-MAS) NMR spectroscopy in the biochemical profile determination of human liver needle biopsy samples for the characterization of metabolic alterations related to the severity of liver disease. We recorded and analyzed HR-MAS spectra of 68 liver tissue samples obtained by needle biopsy from patients with chronic liver disease. Multivariate analysis was applied to these data to obtain discrimination patterns and to reveal relevant metabolites. The metabolic characterization of liver tissue from needle biopsies by HR-MAS NMR spectroscopy provided differential patterns for cirrhotic and non-cirrhotic chronic liver disease tissue. Metabolites closely related to the liver metabolism such as some fatty acids, glucose and amino acids show differences between the two groups. Phospholipid precursors, which have been previously correlated with hepatic lesions also show differences. Furthermore, the correlation between histologically assessed liver disease stages and the levels of the most discriminative metabolites show that liver dysfunction is present at the initial stages of chronic hepatic lesions. Overall, this work suggests that the additional information obtained by NMR metabolomics applied to needle biopsies of human liver may be useful for assessing metabolic alterations and liver dysfunction in chronic liver disease. IntroductionThe liver is among the most metabolically diverse organs of the body and is involved in many critical metabolic processes (1). One of its major roles is storing endogenous fuels of the body. In addition, the liver acts as a major distribution center for exogenous energy supplies. The liver may be affected by many pathological aggressions. Liver dysfunction results in a variety of clinical signs and symptoms. However, some of these pathologies pose a diagnostic challenge as many different diseases show similar clinical signs (2-4). Moreover, liver biopsy assessment involves some degree of complication because of the proliferation of different grading and staging schemes (5-7). Metabolic alterations produced by liver disease may help clinicians better characterize the disease. Among the different processes occurring during the evolution of liver disease, fibrosis takes a predominant role. Liver fibrosis is characterized by the replacement of liver tissue by fibrous scar tissue as well as regenerative nodules, leading to progressive loss of liver function and to altered liver metabolism (8-11). Liver fibrosis induction mechanisms are fairly constant irrespectivel...

show abstract

“…Data on brain cancers also is extensive, with defined metabolomics biomarkers established from studies of brain tumor specimens exhibiting discrete 1 H-NMR spectra (34,35 ). Analysis of tCho by magnetic resonance spectroscopic imaging was able to detect breast, prostate, and brain tumors and correlated well with diagnosis via dynamic contrast-enhanced MRI (35 ).…”

Section: Opportunities From the Cancer Metabolomementioning

confidence: 99%

New Opportunities from the Cancer Metabolome

Aboud¹,

Weiss

2013

Clinical Chemistry

View full text Add to dashboard Cite

BACKGROUND: Metabolomics, the study of all metabolites produced in the body, which often includes flora and drug metabolites, is the omics approach that can be considered most closely related to a patient's phenotype. Metabolomics has a great and largely untapped potential in the field of oncology, and the analysis of the cancer metabolome to identify biofluid markers and novel druggable targets can now be undertaken in many research laboratories. CONTENT:The cancer metabolome has been used to identify and begin to evaluate potential biomarkers and therapeutic targets in a variety of malignancies, including breast, prostate, and kidney cancer. We discuss the several standard techniques for metabolite separation and identification, with their potential problems and drawbacks. Validation of biomarkers and targets may entail intensive use of labor and technology and generally requires a large number of study participants as well as laboratory validation studies. The field of pharmacometabolomics, in which specific therapies are chosen on the basis of a patient's metabolomic profile, has shown some promise in the translation of metabolomics into the arena of personalized medicine.

show abstract

Pattern recognition analysis of ¹H NMR spectra from perchloric acid extracts of human brain tumor biopsies

Cited by 68 publications

References 25 publications

Tumor suppressive activity of a variant isoform of manganese superoxide dismutase released by a human liposarcoma cell line

Tumor suppressive activity of a variant isoform of manganese superoxide dismutase released by a human liposarcoma cell line

Metabolic profile of chronic liver disease by NMR spectroscopy of human biopsies

New Opportunities from the Cancer Metabolome

Contact Info

Product

Resources

About

Pattern recognition analysis of 1H NMR spectra from perchloric acid extracts of human brain tumor biopsies

Cited by 68 publications

References 25 publications

Tumor suppressive activity of a variant isoform of manganese superoxide dismutase released by a human liposarcoma cell line

Tumor suppressive activity of a variant isoform of manganese superoxide dismutase released by a human liposarcoma cell line

Metabolic profile of chronic liver disease by NMR spectroscopy of human biopsies

New Opportunities from the Cancer Metabolome

Contact Info

Product

Resources

About

Pattern recognition analysis of ¹H NMR spectra from perchloric acid extracts of human brain tumor biopsies